Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload
Cornel Badorff, Hartmut Ruetten, Sven Mueller, Meike Stahmer, Doris Gehring, Frank Jung, Christian Ihling, Andreas M. Zeiher, Stefanie Dimmeler
Cornel Badorff, Hartmut Ruetten, Sven Mueller, Meike Stahmer, Doris Gehring, Frank Jung, Christian Ihling, Andreas M. Zeiher, Stefanie Dimmeler
View: Text | PDF
Article

Fas receptor signaling inhibits glycogen synthase kinase 3β and induces cardiac hypertrophy following pressure overload

  • Text
  • PDF
Abstract

Congestive heart failure is a leading cause of mortality in developed countries. Myocardial hypertrophy resulting from hypertension often precedes heart failure. Understanding the signaling underlying cardiac hypertrophy and failure is of major interest. Here, we identified Fas receptor activation, a classical death signal causing apoptosis via activation of the caspase cascade in many cell types, as a novel pathway mediating cardiomyocyte hypertrophy in vitro and in vivo. Fas activation by Fas ligand induced a hypertrophic response in cultured cardiomyocytes, which was dependent on the inactivation of glycogen synthase kinase 3β (GSK3β) by phosphorylation. In vivo, lpr (lymphoproliferative disease) mice lacking a functional Fas receptor demonstrated rapid-onset left ventricular dilatation and failure, absence of compensatory hypertrophy, and significantly increased mortality in response to pressure overload induction that was accompanied by a failure to inhibit GSK3β activity. In contrast, Fas ligand was dispensable for the development of pressure overload hypertrophy in vivo. In vitro, neonatal cardiomyocytes from lpr mice showed a completely abrogated or significantly blunted hypertrophic response after stimulation with Fas ligand or angiotensin II, respectively. These findings indicate that Fas receptor signaling inhibits GSK3β activity in cardiomyocytes and is required for compensation of pressure overload in vivo.

Authors

Cornel Badorff, Hartmut Ruetten, Sven Mueller, Meike Stahmer, Doris Gehring, Frank Jung, Christian Ihling, Andreas M. Zeiher, Stefanie Dimmeler

×

Figure 1

Options: View larger image (or click on image) Download as PowerPoint
Fas ligand induces cardiomyocyte hypertrophy but not apoptosis. (a) Neon...
Fas ligand induces cardiomyocyte hypertrophy but not apoptosis. (a) Neonatal rat cardiomyocytes or Jurkat T lymphocytes were treated with Fas ligand or H2O2, and apoptosis was assessed by DAPI staining. Data are mean ± SEM from four independent experiments. *P < 0.05 versus control. (b) Annexin V staining of rat cardiomyocytes following treatment with Fas ligand or H2O2. (c) [3H] leucine incorporation of rat cardiomyocytes following treatment with Fas ligand, angiotensin II, or endothelin-1. Data are mean ± SEM from four independent experiments. *P < 0.05 versus control. (d) Myosin light chain 2v immunofluorescence of rat cardiomyocytes following treatment with Fas ligand. (e) Increased ANF mRNA detected by Northern blotting following treatment with Fas ligand for the times indicated. Representative images of three independent experiments are shown in c–e.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts